HR Execs on the Move

Standard Bio

www.standardbio.com

 
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.standardbio.com
  • 2 Tower Place Suite 2000
    South San Francisco, CA USA 94080
  • Phone: 650.266.6000

Executives

Name Title Contact Details
Jeffrey Black
 Chief Financial Officer Profile
Vikram Jog
 Chief Financial Officer Profile
Julie Alipaz
 Director R&D Program Management Profile
Brian Fowler
 Director, Research and Development Profile
Massimo Carli
 Director - Organizational and Talent Development Profile

Similar Companies

GenWay Biotech

GenWay Biotech is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Stallergenes

Stallergenes is a Norwell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Artel

Artel is the global technology leader in ultra low volume liquid delivery measurement and quality assurance. The company develops and manufactures the most accurate, precise and easy-to-use systems available for ensuring liquid delivery data integrity and NIST-traceable results in life sciences laboratories. Artel innovations help laboratories improve processes and increase productivity, enhance product quality, and address compliance challenges.

Arcellx

Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx`s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx`s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, expected to enter the clinic in the second half of 2022.

MediGene

MediGene, Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.